AHA 2025

Extensive data on novel triglyceride-lowering agents were presented at the American Heart Association Scientific Sessions in New Orleans (7-10 November 2025), including from the Phase 3 CORE-TIMI 72a and CORE2-TIMI 72b studies of olezarsen in severe hypertriglyceridaemia, a first-in-human study of ANGPTL3 gene editing, and a Phase 2 study of a triple action TG-lowering agent. […]

Full data from the Phase 3 CORE-TIMI 72a and CORE2-TIMI 72b studies of olezarsen in a total of 1,061 patients with severe hypertriglyceridaemia (sHTG) confirm the promising top line findings announced earlier this year. There was a significant placebo-adjusted mean reduction in fasting TG levels of up to 72% at six months (p<0.001), remaining stable […]

A one-time infusion of an investigational ANGPTL3-targeting CRISPR-Cas9 therapy, CTX310, reduced TG by approximately 55% and LDL-C by up to approximately 50%. These were the key findings from a Phase 1 first-in-human, single ascending dose study of CTX310 i.v. administered to 15 adults with uncontrolled hypercholesterolaemia, hypertriglyceridaemia or mixed dyslipidaemia while on maximally tolerated medical […]

The novel FGF21 receptor/glucagon receptor/GLP-1 receptor triple agonist, DR10624, in doses of 12.5 mg, 25 mg and 50 mg reduces TG by 74.5%, 66.2% and 68.9% respectively, according to results of a Phase 2, 12-week study in 79 patients with severe hypertriglyceridaemia (500-2000 mg/dL). This compared with an 8% TG reduction in patients who received […]

Pemafibrate significantly reduced fibrinogen levels in patients with coronary artery disease (CAD) and hypertriglyceridaemia (HTG), highlighting its primary benefit in lowering thrombotic risk, concluded researchers who carried out a multicentre, randomised, controlled trial to evaluate the effect of pemafibrate on fibrinogen levels in patients with CAD and HTG undergoing antiplatelet monotherapy and statin therapy.